Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
life sciences
national
national blog main
national top stories
new york top stories
san francisco top stories
6
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
novartis
eli lilly
fda
fremanezumab
teva pharmaceutical
alder biopharmaceuticals
biogen
bristol-myers squibb
calcitonin gene-related peptide
cancer
cell therapy
What
drug
6
×
new
6
×
approval
fda
bio
class
companies
drugs
migraine
oral
patients
roundup
won
advantages
amgen
approved
arguments
atrophy
bar
big
biogen’s
biopharmaceutical
brings
candidates
cholesterol
commercialized
competitors
convo
daily
decades
developed
earlier
evrysdi
expect
expensive
faces
failures
financial
foe
friday
Language
unset
Current search:
drug
×
biotech
×
" san francisco top stories "
×
new
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines